Abstract:Phosphoinositide 3-kinase (PI3K) was an important cellular signal transducer, while PI3Kα was the most mutated family member in cancer. Selective PI3Kα inhibitors have become the frequent research in recent years because of their excellent curative effect and reduced side effects. Here, we described a series of PI3Kα inhibitors with 1,3,5-triazine or pyrimidine skeleton containing benzoyl hydrazine based on the pan-PI3K inhibitor ZSTK474 relying on the strategies of structure-based drug discovery (SBDD) and computer-aided drug design (CADD). Among them, compound F8 exhibited improved selective PI3Kα inhibition with an IC50 value of 0.14 nM and more significant anti-proliferative activities against three tumor-derived cell lines (PC-3 IC50 = 0.28 μM, HCT-116 IC50 = 0.57 μM, and U87-MG IC50 = 1.37 μM) than ZSTK-474. Compound F-8 induced a great decrease in mitochondrial membrane which caused cell cycle arrest at G1 phase and apoptosis in U87-MG cells in a dose-dependent manner. Furthermore, compound F8 induced significant tumor regressions in a xenograft mouse model of U87-MG cell line with no clear evidence of toxicity following intraperitoneal injection of 40 mg/kg. Compound F8 may serve as a PI3Kα-selective inhibitor and provided the opportunity to spare patients the side effects associated with broader inhibition of the class I PI3K family.

6,7-Dihydrobenzo[f]benzo[4,5]imidazo[1,2-d][1,4]oxazepine Derivatives As Selective Inhibitors of PI3Kα

Discovery and Synthesis of a Novel Series of Potent, Selective Inhibitors of the PI3Kα: 2-Alkyl-chromeno[4,3-c]pyrazol-4(2h)-one Derivatives.

Design, Synthesis and Biological Evaluation of 1-Phenanthryl-tetrahydroisoquinoline Derivatives As Novel P21-Activated Kinase 4 (PAK4) Inhibitors.

Development of small-molecule inhibitors that target PI3K13

Development of New Thiophene-Containing Triaryl Pyrazoline Derivatives as PI3Kγ Inhibitors

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-<i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.

Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies

Design, synthesis and bioevaluation of PI3Kα-selective inhibitors as potential colorectal cancer drugs

Discovery of a Series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides As PI3K/mTOR Dual Inhibitors

Structure-based drug design, synthesis, and biological evaluation of novel 1,3,5-triazine or pyrimidine derivatives containing benzoyl hydrazine moiety as PI3Kα selective inhibitors

Discovery of Chromeno[4,3-c]pyrazol-4(2H)-one Containing Carbonyl or Oxime Derivatives As Potential, Selective Inhibitors PI3Kα.

Discovery of Pyrazolo[1,5- a ]pyridine Derivatives as Potent and Selective PI3Kγ/δ Inhibitors

Structurally Novel PI3Kδ/γ Dual Inhibitors Characterized by a Seven-Membered Spirocyclic Spacer: the SARs Investigation and PK Evaluation.

Development of Novel Chromeno[4,3-C]pyrazol-4(2h)-one Derivates Bearing Sulfonylpiperazine As Antitumor Inhibitors Targeting PI3Kα.

Conformationally Restricted Quinazolone Derivatives As PI3Kδ-selective Inhibitors: the Design, Synthesis and Biological Evaluation.

Design And Synthesis Of A Novel Series Of N,4-Diphenylpyrimidin-2-Amine Derivatives As Potent And Selective Pi3k Gamma Inhibitors

Synthesis and Biological Evaluation of Novel 2-Arylamino-3-(arylsulfonyl)quinoxalines As PI3Kα Inhibitors

Design, Synthesis and Biological Evaluation of Novel 4-Alkynyl-quinoline Derivatives As PI3K/mTOR Dual Inhibitors.

Novel 4-Acrylamido-quinoline Derivatives As Potent PI3K/mTOR Dual Inhibitors: the Design, Synthesis, and in Vitro and in Vivo Biological Evaluation.

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors